Libre Cgms News Today

At the Advanced Technologies & Treatments for Diabetes meeting, two clinical experts gave advice for helping patients with type 1 diabetes optimize CGM use.

These growth stocks are raking in profits and cash as leaders in their respective industries.

Its latest pullback could be an opportunity to buy a legendary dividend stock before it begins a long upward climb.

Abbott CEO Robert Ford says the company has now seen two quarters in a row of double-digit organic sales growth in its underlying business.

/PRNewswire/ -- The global blood glucose meters industry size was valued at USD 15.80 billion in 2022 and will register a robust CAGR of around 7.3% from 2023...